BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27035536)

  • 21. A word to the wise about ketamine.
    Schatzberg AF
    Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
    [No Abstract]   [Full Text] [Related]  

  • 22. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
    Abdallah CG; Adams TG; Kelmendi B; Esterlis I; Sanacora G; Krystal JH
    Depress Anxiety; 2016 Aug; 33(8):689-97. PubMed ID: 27062302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
    Kellner CH; Greenberg RM; Ahle GM; Liebman LS
    Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
    [No Abstract]   [Full Text] [Related]  

  • 24. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid antidepressant effects of ketamine ignite drug discovery.
    Dolgin E
    Nat Med; 2013 Jan; 19(1):8. PubMed ID: 23295995
    [No Abstract]   [Full Text] [Related]  

  • 26. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
    Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
    J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving Issues in the Treatment of Depression.
    Köhler-Forsberg O; Cusin C; Nierenberg AA
    JAMA; 2019 Jun; 321(24):2401-2402. PubMed ID: 31125042
    [No Abstract]   [Full Text] [Related]  

  • 31. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
    Lundin NB; Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Brutsche NE; Machado-Vieira R; Zarate CA
    Pharmacopsychiatry; 2014 Jul; 47(4-5):141-4. PubMed ID: 24955551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained antidepressant response to ketamine.
    Atigari OV; Healy D
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23960151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant effects of ketamine in depressed patients.
    Berman RM; Cappiello A; Anand A; Oren DA; Heninger GR; Charney DS; Krystal JH
    Biol Psychiatry; 2000 Feb; 47(4):351-4. PubMed ID: 10686270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
    Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
    J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
    Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of dissociation in ketamine's antidepressant effects.
    Ballard ED; Zarate CA
    Nat Commun; 2020 Dec; 11(1):6431. PubMed ID: 33353946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.
    Hashimoto K
    Psychopharmacology (Berl); 2014 Oct; 231(20):4081-2. PubMed ID: 25189793
    [No Abstract]   [Full Text] [Related]  

  • 38. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
    Hashimoto K
    J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
    [No Abstract]   [Full Text] [Related]  

  • 39. Ketamine's effectiveness in unipolar versus bipolar depression.
    Fond G; Boyer L
    Psychopharmacology (Berl); 2014 Nov; 231(22):4417-8. PubMed ID: 25315362
    [No Abstract]   [Full Text] [Related]  

  • 40. Investigational drugs for treating major depressive disorder.
    Dhir A
    Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.